- Home
- LAES vs ITOS Comparison
LAES vs ITOS Comparison
Compare LAES & ITOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LAES
- ITOS
- Stock Information
- Founded
- LAES 2022
- ITOS 2011
- Country
- LAES Switzerland
- ITOS United States
- Employees
- LAES N/A
- ITOS N/A
- Industry
- LAES Semiconductors
- ITOS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LAES Technology
- ITOS Health Care
- Exchange
- LAES Nasdaq
- ITOS Nasdaq
- Market Cap
- LAES 453.6M
- ITOS 381.2M
- IPO Year
- LAES N/A
- ITOS 2020
- Fundamental
- Price
- LAES $3.36
- ITOS $10.31
- Analyst Decision
- LAES Strong Buy
- ITOS Hold
- Analyst Count
- LAES 1
- ITOS 6
- Target Price
- LAES $6.00
- ITOS $10.60
- AVG Volume (30 Days)
- LAES 10.7M
- ITOS 782.2K
- Earning Date
- LAES 07-22-2025
- ITOS 08-07-2025
- Dividend Yield
- LAES N/A
- ITOS N/A
- EPS Growth
- LAES N/A
- ITOS N/A
- EPS
- LAES N/A
- ITOS N/A
- Revenue
- LAES $10,981,000.00
- ITOS $35,000,000.00
- Revenue This Year
- LAES N/A
- ITOS N/A
- Revenue Next Year
- LAES N/A
- ITOS N/A
- P/E Ratio
- LAES N/A
- ITOS N/A
- Revenue Growth
- LAES N/A
- ITOS 177.89
- 52 Week Low
- LAES $0.29
- ITOS $4.80
- 52 Week High
- LAES $11.00
- ITOS $18.13
- Technical
- Relative Strength Index (RSI)
- LAES 41.35
- ITOS 66.98
- Support Level
- LAES $3.31
- ITOS $10.13
- Resistance Level
- LAES $4.28
- ITOS $10.41
- Average True Range (ATR)
- LAES 0.30
- ITOS 0.13
- MACD
- LAES -0.11
- ITOS -0.04
- Stochastic Oscillator
- LAES 3.77
- ITOS 80.00
About LAES SEALSQ Corp
SEALSQ Corp develops certified secure microcontrollers and implements post-quantum cryptography. The company develops solutions including post-quantum microchips and devices that can be used in a variety of applications, from multi-factor authentication, home automation, and IT network infrastructure to automotive, industrial automation, and control systems. The company's vaultIC range offers a set of ready-to-use secure elements designed to implement embedded security for any kind of device with fast time-to-market and high flexibility. The company's products include VaultIC155, VaultIV18x, VaultIC292, and VaultIC40x. The company generates a majority of its revenue from North America.
About ITOS iTeos Therapeutics Inc.
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.